- Report
- October 2024
- 180 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- April 2024
- 89 Pages
Middle East, Africa
From €3293EUR$3,450USD£2,759GBP
- Report
- July 2022
- 100 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- November 2024
- 78 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- August 2023
- 104 Pages
Global
From €3500EUR$3,929USD£3,035GBP
The Extracorporeal Blood Treatment market is a subset of the Cardiovascular Devices market. It includes devices used to treat a variety of cardiovascular conditions, such as heart failure, coronary artery disease, and arrhythmias. These devices are used to remove blood from the body, treat it, and then return it to the body. This process is known as extracorporeal blood treatment (EBT). Examples of EBT devices include extracorporeal membrane oxygenation (ECMO) systems, ventricular assist devices (VADs), and extracorporeal shock wave lithotripsy (ESWL) systems.
EBT devices are used to improve the quality of life of patients with cardiovascular conditions, as well as to reduce the risk of complications. They are also used to reduce the need for invasive procedures, such as open heart surgery.
Some of the major companies in the Extracorporeal Blood Treatment market include Medtronic, Abbott, Terumo, and Fresenius Medical Care. Show Less Read more